Abstract
Background: We describe an 8-month-old boy with leukemia and SARS-CoV-2 infection who developed Kasabach-Merritt phenomenon. He had a positive SARS-COV-2 RT-PCR sample. Hematologic tests showed coagulopathy and intestinal involvement. She was managed in emergency receiving transfusion support and in hospitalization with social isolation measures, she started propanolol and corticotherapy as initial treatment of infantile angiomas. She presented with symptoms of intestinal obstruction and underwent surgery and evidence of hemorrhagic infarction with foci of intestinal ischemic necrosis, ending in ileostomy. We tried to understand a pathophysiological explanation of the dermatologic and gastrointestinal tract involvement by the virus and the atypical form of COVID-19. Given the emerging evidence of endothelial and vascular involvement in COVID-19, the development of tests to detect vascular lesions may be critical to guide the use of new therapeutic strategies.
Highlights
The association between giant hemangioma and thrombocytopenia was described by Haig Kasabach and Katharine Merritt in 1940(1)
Kasabach Merritt syndrome is usually a rapidly growing vascular anomaly causing consumingcoagulopathy, thrombocytopenia, hypofibrinogenemia, Dimero d high, microangiopathic hemolytic anemia, prolonged prothrombin time and partial thromboplastin time; this syndrome is 90% associated with Kaposiform Hemangioendothelioma[2,3]
An 8-month-old boy with debut of acute lymphoblastic leukemia and angioma infantile who presented with Kasabach Merritt syndrome precipitated by SARS-CoV-2 infection
Summary
SARS-CoV-2 precipitated Kasabach-Merritt syndrome in a child with angioma infantile and acute lymphoblastic leukemia: Case Report.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
